Comparing Two Forms of Metacognitive Training for Psychosis
Compares standard and personalized metacognitive training in adults with schizophrenia spectrum disorder.
Plain-language title generated from the registry record
Registry title: Personalized Metacognitive Training for Psychosis: A Randomized Controlled Trial
Key facts
- Where
- Strasbourg, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07146802, who can take part
Where in France
- Service de psychiatrieStrasbourg, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Strasbourg, France
- Trial code
- NCT07146802
- Record updated
- 20 August 2026
- Original description
This study aims to compare the efficacy of classical Metacognitive Training (MCT) and personalized Metacognitive Training (P-MCT) for individuals with psychosis. MCT is a psychoeducational program derived from cognitive-behavioral therapy (CBT) that targets cognitive biases associated with psychotic symptoms. The goal is to assess which intervention is more effective to improve the overall functioning of individuals with psychosis. The study will use machine learning to personalize the treatment approach and evaluate its impact on clinical symptoms, cognitive functions, and quality of life.Read full original descriptionShow less
Towards a Personalized Medicine Approach to Psychological Treatment for Psychosis
This study aims to compare the efficacy of classical Metacognitive Training (MCT) and personalized Metacognitive Training (P-MCT) for individuals with psychosis. MCT is a psychoeducational program derived from cognitive-behavioral therapy (CBT) that targets cognitive biases associated with psychotic symptoms. The goal is to assess which intervention is more effective to improve the overall functioning of individuals with psychosis. The study will use machine learning to personalize the treatment approach and evaluate its impact on clinical symptoms, cognitive functions, and quality of life.
Inclusion: Adults, 18 - 65 years of age; Patient affiliated to health insurance; Inpatients and outpatients with DSM-5 diagnosis of schizophrenia spectrum disorder; Presence of positive symptoms at inclusion (PANSS delusions, suspiciousness or grandiosity ≥3); Stable condition with no expected changes in medication or symptoms during the last 3 months (information from clinical services, note that stable condition includes lack of suicidality); Patient providing informed consent.
Exclusion: Having received MCT in the previous year; Patient considered by his psychiatrist to be at serious risk of harm to self or others (e.g. previous aggressive or suicidal behaviors); Neurological disorder, or severe medical condition other than psychosis; A score above 5 in the "Hostility" and the "Suspiciousness" items of the PANSS Positive subscale (to preserve group dynamics); Patient in an exclusion period defined by another research protocol; Patient involved in another Investigational Medicinal Product trial; Patient under guardianship (i.e. French "tutelle"); Patients deprived of freedom because of a judicial measure.